Oxilio and Quotient Sciences Announce Regulatory Approval fo

NOTTINGHAM, England, Sept. 29, 2022 /PRNewswire/ -- Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, and Quotient Sciences

Related Keywords

United Kingdom , Nottingham , Prnewswire Oxilio , Trx Biosciences , Kostenloser Wertpapierhandel , Mark Egerton , Simon Yaxley , Research Ethics Committee , Quotient Sciences Translational Pharmaceutics , Quotient Sciences , Regulatory Agency , United Kingdom Medicines , Clinical Trial Application , Quotient Science , Translational Pharmaceutics , Oxilio , Quotient , Ciences , Nnounce , Egulatory , Approval , Xl001 , Development , Program ,